Intracerebral administration of protein kinase A or cAMP response element-binding protein antisense oligonucleotide can modulate amphetamine-mediated appetite suppression in free-moving rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 292, Issue 1, 2007, Pages

  Hsieh, Yih Shou ^a   Yang, Shun Fa ^a   Kuo, Dong Yih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Amphetamine; Feeding behavior; Neuropeptide Y; Signaling transduction

Indexed keywords

AMPHETAMINE; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MESSENGER RNA; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DOWN REGULATION; FEEDING BEHAVIOR; GENE CONTROL; GENE EXPRESSION; HYPOTHALAMUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

AMPHETAMINE; ANIMALS; ANOREXIA; APPETITE DEPRESSANTS; APPETITE REGULATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEEDING BEHAVIOR; INJECTIONS, INTRAVENTRICULAR; MALE; MOVEMENT; NERVE TISSUE PROTEINS; NEUROPEPTIDE Y; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 33846025964     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00195.2006     Document Type: Article

References (64)

1. Akabayashi A, Zaia CT, Gabriel SM, Silva I, Cheung WK, Leibowitz SF. Intracerebroventricular injection of dibutyryl cyclic adenosine 3′,5′-monophosphate increases hypothalamic levels of neuropeptide Y. Brain Res 660: 323-328, 1994.
2. Andersson M, Konradi C, Cenci MA. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21: 9930-9943, 2001.
3. Battaini F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol Res 44: 353-361, 2001.
4. Beninger RJ, Gerdjikov T. The role of signaling molecules in reward-related incentive learning. Neurotox Res 6: 91-104, 2004.
5. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10: 16-25, 2005.
6. Biel JH, Bopp BA. Amphetamine: structure-activity relationship. In: Handbook of Psychopharmacology, edited by Iversen LL, Iversen SD, and Snyder SH. New York: Plenum, 1978, p. 1-39.
7. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol Regul Integr Comp Physiol 266: R1765-R1770, 1994.
8. Chance WT, Sheriff S, Balasubramaniam A. Antagonism of NPY-induced feeding by pretreatment with cyclic AMP response element binding protein antisense oligonucleotide. Neuropeptides 34: 167-172, 2000.
9. Chiasson BJ, Hooper ML, Murphy PR, Robertson HA. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur J Pharmacol 227: 451-453, 1992.
10. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid quanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
11. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 143: 380-385, 2005.
12. Crawford CA, Choi FY, Kohutek JL, Yoshida ST, McDougall SA. Changes in PKA activity and Gs alpha and Golf alpha levels after amphetamine- and cocaine-induced behavioral sensitization. Synapse 51: 241-248, 2004.
13. Das S, Grunert M, Williams L, Vincent SR. NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture. Synapse 25: 227-233, 1997.
14. Dominguez G, Kuhar MJ. Transcriptional regulation of the CART promoter in CATH.a cells. Brain Res Mol Brain Res 126: 22-29, 2004.
15. Fiala A, Muller U, Menzel R. Reversible downregulation of protein kinase A during olfactory learning using antisense technique impairs long-term memory formation in the honeybee, Apis mellifera. J Neurosci 19: 10125-10134, 1999.
16. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 1016: 90-95, 2004.
17. Ghosh MK, Cohen JS. Oligodeoxynucleotides as antisense inhibitors of gene expression. Prog Nucleic Acid Res Mol Biol 42: 79-126, 1992.
18. Griffioen G, Thevelein JM. Molecular mechanisms controlling the localization of protein kinase A. Curr Genet 41: 199-207, 2002.
19. Habener JF, Miller CP, Vallejo M. cAMP-dependent regulation of gene transcription by cAMP response element-binding protein and cAMP response element modulator. Vitam Horm 51: 1-57, 1995.
20. Higuchi H, Yang HYT, Sabol SL. Rat neuropeptide Y precursor gene expression: mRNA structure, tissue distribution, and regulation by glucocorticoids, cyclic AMP, and phorbol ester. J Biol Chem 263: 6288-6295, 1988.
21. Hsieh YH, Yang SF, Chiou HL, Kuo DY. Transcriptional involvement of protein kinase C-alpha isozyme in amphetamine-mediated appetite suppression. Eur J Neurosci 22: 715-723, 2005.
22. Hulsey MG, Pless CM, Whit BD, Martin RJ. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regul Pept 59: 207-214, 1995.
23. Itoi K, Horiba N, Tozawa F, Sakai Y, Sakai K, Abe K, Demura H, Suda T. Major role of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. Endocrinology 137: 2389-2396, 1996.
24. Kalra SP, Kalra PS. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides 38: 201-211, 2004.
25. 2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52: 948-956, 2003.
26. Konradi C, Cole RL, Heckers S, Hyman SE. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 14: 5623-5634, 1994.
27. Kuo DY. Involvement of hypothalamic neuropeptide Y in regulating the amphetamine-induced appetite suppression in streptozotocin diabetic rats. Regul Pept 127: 19-26, 2005.
28. Kuo DY. Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and cerebral neuropeptide Y (NPY) in amphetamine-induced appetite suppression. Behav Brain Res 147: 149-155, 2003.
29. Kuo DY, Cheng JT. Role of cerebral dopamine but not plasma insulin, leptin and glucocorticoid in the development of tolerance to the anorectic effect of amphetamine. Neurosci Res 44: 63-69, 2002.
30. Kuo DY, Hsu CT, Cheng JT. Role of hypothalamic neuropeptide Y (NPY) in the change of feeding behavior induced by repeated treatment of amphetamine. Life Sci 70: 243-251, 2001.
31. Lambert PD, Couceyro PR, McGirr KM, Dall Vechia SE, Smith Y, Kuhar MJ. CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse 29: 293-298, 1998.
32. Larhammar D, Ericsson A, Persson H. Structure and expression of the rat neuropeptide Y gene. Proc Natl Acad Sci USA 84: 2068-2072, 1987.
33. Leibowitz SF. Catecholaminergic mechanisms of the lateral hypothalamus: their role in the mediation of amphetamine anorexia. Brain Res 98: 529-545, 1975.
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
35. Magni P, Barnea A. Forskolin and phorbol ester stimulation of neuropeptide Y (NPY) production and secretion by aggregating fetal brain cells in culture: evidence for regulation of NPY biosynthesis at transcriptional and posttranscriptional levels. Endocrinology 130: 976-984, 1992.
36. Morris BJ. Neuronal localization of neuropeptide Y gene expression in rat brain. J Comp Neurol 290: 358-368, 1989.
37. Morrison CD, Morton GJ, Niswender KD, Gelling RW, Schwartz MW. Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 289: E1051-E1057, 2005.
38. Nichols DE. Medicinal chemistry and structure-activity relationships. In: Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse, edited by Cho AK and Segal DS. San Deigo, CA: Academic, 1994, p.3-41.
39. Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol 285: C334-C342, 2003.
40. Ogawa S, Brown HE, Okano HJ, Pfaff DW. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul Pept 59: 143-149, 1995.
41. Ogawa S, Pfaff DW. Current status of antisense DNA methods in behavioral studies. Chem Senses 23: 249-255, 1998.
42. Olson VG, Zabetian CP, Bolanos CA, Edwards S, Barrot M, Eisch AJ, Hughes T, Self DW, Neve RL, Nestler EJ. Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area. J Neurosci 25: 5553-5562, 2005.
43. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates (2nd ed.). Sydney, Australia: Academic, 1986.
44. Ritter RC, Slusser PG, Stone S. Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. Science 213: 451-452, 1981.
45. Sawchenko PE, Swanson LW, Grzanna R, Howe PR, Bloom SR, Polak JM. Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J Comp Neurol 241: 138-153, 1985.
46. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 23: 639-677, 1993.
47. Shaw-Lutchman TZ, Impey S, Storm D, Nestler EJ. Regulation of CRE-mediated transcription in mouse brain by amphetamine. Synapse 48: 10-17, 2003.
48. Sheriff S, Chance WT, Iqbal S, Rizvi TA, Xiao C, Kasckow JW, Balasubramaniam A. Hypothalamic administration of cAMP agonist/PKA activator inhibits both schedule feeding and NPY-induced feeding in rats. Peptides 24: 245-254, 2003.
49. Sheriff S, Chance WT, Fischer JE, Balasubramaniam A. Neuropeptide Y treatment and food deprivation increase cyclic AMP response element-binding in rat hypothalamus. Mol Pharmacol 51: 597-604, 1997.
50. Shimizu-Albergine M, Ippolito DL, Beavo JA. Downregulation of fasting-induced cAMP response element-mediated gene induction by leptin in neuropeptide Y neurons of the arcuate nucleus. J Neurosci 21: 1238-1246, 2001.
51. Skrinska VA, Gock SB. Measurement of 3,4-MDMA and related amines in diagnostic and forensic laboratories. Clin Lab Sci 18: 119-123, 2005.
52. Sternberger LA, Sternberger NH. The unlabeled antibody method: comparison of peroxidase-antiperoxidase with avidin-biotin complex by a new method of quantification. J Histochem Cytochem 34: 509-605, 1986.
53. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15: 4102-4108, 1995.
54. Sutton MA, McGibney K, Beninger RJ. Conditioned locomotion in rats following amphetamine infusion into the nucleus accumbens: blockade by coincident inhibition of protein kinase A. Behav Pharmacol 11: 365-376, 2000.
55. Taminato A, Bagattini R, Gorjao R, Chen G, Kuspa A, Souza GM. Role for YakA, cAMP, and protein kinase A in regulation of stress responses of Dictyostelium discoideum cells. Mol Biol Cell 13: 2266-2275, 2002.
56. Tasken K, Skalhegg BS, Tasken KA, Solber R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, Jahnsen T. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 31: 191-204, 1997.
57. Tolliver BK, Ho LB, Fox LM, Berger SP. Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventral tegmental area amphetamine. J Pharmacol Exp Ther 289: 38-47, 1999.
58. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 15: 42-46, 1994.
59. Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger JR, Neckers LM. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 90: 4665-4669, 1993.
60. Widnell KL, Self DW, Lane SB, Russell DS, Vaidya V, Miserendino MJD, Rubin CS, Duman RS, Nestler EJ. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. J Pharmacol Exp Ther 276: 306-315, 1996.
61. Woods SC, Figlewicz DP, Madden L, Porte D Jr, Sipols AJ, Seeley RJ. NPY and food intake: discrepancies in the model. Regul Pept 75: 403-408, 1998.
62. Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287: 107-114, 1998.
63. Yee F, Ericson H, Reis DJ, Wahlestedt C. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. Cell Mol Neurobiol 14: 475-486, 1994.
64. Zhang M, Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci Lett 161: 223-226, 1993.